Michelle McDade, MD
Addiction Medicine · New Britain, CTNPI 1801820972
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 48.6% of the total.
Across 15 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$126
- Purdue Pharma L.p.$39
- AstraZeneca$31
- Johnson & Johnson$18
- CSL Behring$17
- Gilead$15
- plus $13 from 1 others
What the payments were for
- Food & beverage$259100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 7 | $126 |
| Purdue Pharma L.p. | 2 | $39 |
| AstraZeneca(2 entities) | 2 | $31 |
| Johnson & Johnson | 1 | $18 |
| CSL Behring | 1 | $17 |
| Gilead | 1 | $15 |
| Pfizer | 1 | $13 |
How this compares
$259 in reported general payments places this provider in the 55th percentile of 28 addiction medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Esomeprazole Magnesium | 21 | $272 |
| Doxycycline Hyclate | 26 | $168 |
| Ondansetron OdtOndansetron | 18 | $137 |
| Famotidine | 30 | $135 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 14 | $134 |
| Cyclobenzaprine Hcl | 29 | $113 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 28 | $113 |
| Meloxicam | 57 | $79 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 17 | $75 |
| Promethazine Hcl | 17 | $72 |
| Methylprednisolone | 11 | $71 |
| Ibuprofen | 21 | $53 |
| Prednisone | 23 | $27 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in New Britain
- Jenna ButnerNew Haven$27K
- Ayaz MadraswallaPutnam$14K
- Neal LakritzEnfield$3K
- Mahboob AslamRocky Hill$2K
- Thomas DefantiNorth Stonington$1K
- Edith HerganRocky Hill$1K
- John AntonucciNewington$1K
- Brian KarsifNew Haven$528
- Jay BensonRocky Hill$393
- Sijie WangFarmington$387
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.